Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Epigallocatechin-3-gallate (EGCG) for Supportive and Symptomatic Management in Patients With Esophageal Cancer

NCT05039983 is registered in ClinicalTrials.gov with Shandong Cancer Hospital and Institute as lead sponsor.

NCT NCT05039983
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05039983 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Epigallocatechin-3-gallate (EGCG) for Supportive and Symptomatic Management in Patients With Esophageal Cancer
Lead sponsor
Shandong Cancer Hospital and Institute
Phase
Phase 1
Overall status
Completed
Start date
August 20, 2021
Completion date
January 2, 2024
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal obstruction